5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      EZH2-Myc driven glioblastoma elicited by cytomegalovirus infection of human astrocytes

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Mounting evidence is identifying human cytomegalovirus (HCMV) as a potential oncogenic virus. HCMV has been detected in malignant gliomas. EZH2 and Myc play a potential oncogenic role, correlating with the glioma grade. Herewith, we present the first experimental evidence for HCMV as a reprogramming vector, straight through the dedifferentiation of mature human astrocytes, and generation of CMV-Elicited Glioblastoma Cells (CEGBCs) possessing glioblastoma-like traits. HCMV counterparts the progression of the perceived cellular and molecular mechanisms succeeding the transformation and invasion processes with CEGBCs involved in spheroid formation and invasiveness. Glioblastoma multiforme (GBM) biopsies were characterized by an elevated EZH2 and Myc expression, possessing a strong positive correlation between the aforementioned markers in the presence of HCMV. From GBM tissues, we isolated HCMV clinical strains that transformed HAs toward CEGBCs exhibiting upregulated EZH2 and Myc. Spheroids generated from CEGBCs possessed invasion potential and were sensitive to EZH2 inhibitor, ganciclovir, and temozolomide triple therapy. HCMV clinical strains transform HAs and fit with an HCMV-induced glioblastoma model of oncogenesis, and supports the tumorigenic properties of Myc and EZH2 which might be highly pertinent in the pathophysiology of astrocytic brain tumors and thereby paving the way for new therapeutic strategies.

          Related collections

          Most cited references65

          • Record: found
          • Abstract: found
          • Article: not found

          The 2021 WHO Classification of Tumors of the Central Nervous System: a summary

          The fifth edition of the WHO Classification of Tumors of the Central Nervous System (CNS), published in 2021, is the sixth version of the international standard for the classification of brain and spinal cord tumors. Building on the 2016 updated fourth edition and the work of the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy, the 2021 fifth edition introduces major changes that advance the role of molecular diagnostics in CNS tumor classification. At the same time, it remains wedded to other established approaches to tumor diagnosis such as histology and immunohistochemistry. In doing so, the fifth edition establishes some different approaches to both CNS tumor nomenclature and grading and it emphasizes the importance of integrated diagnoses and layered reports. New tumor types and subtypes are introduced, some based on novel diagnostic technologies such as DNA methylome profiling. The present review summarizes the major general changes in the 2021 fifth edition classification and the specific changes in each taxonomic category. It is hoped that this summary provides an overview to facilitate more in-depth exploration of the entire fifth edition of the WHO Classification of Tumors of the Central Nervous System.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors.

            Cancer cells possess traits reminiscent of those ascribed to normal stem cells. It is unclear, however, whether these phenotypic similarities reflect the activity of common molecular pathways. Here, we analyze the enrichment patterns of gene sets associated with embryonic stem (ES) cell identity in the expression profiles of various human tumor types. We find that histologically poorly differentiated tumors show preferential overexpression of genes normally enriched in ES cells, combined with preferential repression of Polycomb-regulated genes. Moreover, activation targets of Nanog, Oct4, Sox2 and c-Myc are more frequently overexpressed in poorly differentiated tumors than in well-differentiated tumors. In breast cancers, this ES-like signature is associated with high-grade estrogen receptor (ER)-negative tumors, often of the basal-like subtype, and with poor clinical outcome. The ES signature is also present in poorly differentiated glioblastomas and bladder carcinomas. We identify a subset of ES cell-associated transcription regulators that are highly expressed in poorly differentiated tumors. Our results reveal a previously unknown link between genes associated with ES cell identity and the histopathological traits of tumors and support the possibility that these genes contribute to stem cell-like phenotypes shown by many tumors.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Human glioblastoma arises from subventricular zone cells with low-level driver mutations

                Bookmark

                Author and article information

                Contributors
                georges.herbein@univ-fcomte.fr
                Journal
                Oncogene
                Oncogene
                Oncogene
                Nature Publishing Group UK (London )
                0950-9232
                1476-5594
                5 May 2023
                5 May 2023
                2023
                : 42
                : 24
                : 2031-2045
                Affiliations
                [1 ]GRID grid.7459.f, ISNI 0000 0001 2188 3779, Department of Pathogens & Inflammation-EPILAB Laboratory EA4266, University of Franche-Comté, ; Besançon, France
                [2 ]GRID grid.411158.8, ISNI 0000 0004 0638 9213, Department of Pathology, , CHU Besançon, ; Besançon, France
                [3 ]GRID grid.411158.8, ISNI 0000 0004 0638 9213, Department of Virology, , CHU Besançon, ; Besançon, France
                Author information
                http://orcid.org/0000-0002-2984-5870
                http://orcid.org/0000-0002-9291-797X
                http://orcid.org/0000-0001-5375-0874
                http://orcid.org/0000-0002-7993-0221
                Article
                2709
                10.1038/s41388-023-02709-3
                10256614
                37147437
                7ae1a4d2-8424-45e4-866e-11a5ece412a9
                © The Author(s) 2023

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 16 March 2023
                : 20 April 2023
                : 21 April 2023
                Funding
                Funded by: FundRef https://doi.org/10.13039/501100004099, Ligue Contre le Cancer;
                Award ID: CR3304
                Award Recipient :
                Funded by: Université de Franche-Comté (CR3300); Région Franche-Comté(2021-Y-08292 and 2021-Y-08290)
                Funded by: Université de Franche-Comté CR3300
                Funded by: FundRef https://doi.org/10.13039/501100001665, Agence Nationale de la Recherche (French National Research Agency);
                Award ID: COVIDCONTROL
                Award Recipient :
                Funded by: CHU Besançon
                Categories
                Article
                Custom metadata
                © Springer Nature Limited 2023

                Oncology & Radiotherapy
                cancer,cell biology
                Oncology & Radiotherapy
                cancer, cell biology

                Comments

                Comment on this article